RG
KYMR icon

Redmile Group’s Kymera Therapeutics KYMR Stock Holding History

Redmile Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-803,289
Closed -$35.1M – 45
2025
Q2 		$35.1M Sell
803,289
-180,124
-18% -$6.2M 3.73% 12
2025
Q1 		$26.9M Sell
983,413
-117,019
-11% -$4.27M 2.54% 13
2024
Q4 		$44.3M Sell
1,100,432
-292,824
-21% -$13.2M 3.09% 10
2024
Q3 		$65.9M Sell
1,393,256
-186,019
-12% -$8.21M 3.88% 5
2024
Q2 		$47.1M Sell
1,579,275
-154,814
-9% -$5.36M 2.85% 10
2024
Q1 		$69.7M Sell
1,734,089
-89,867
-5% -$3.22M 2.56% 8
2023
Q4 		$46.4M Sell
1,823,956
-44,551
-2% -$797K 1.66% 17
2023
Q3 		$26M Hold
1,868,507
– – 1.24% 26
2023
Q2 		$43M Sell
1,868,507
-542,262
-22% -$15.5M 1.65% 17
2023
Q1 		$71.4M Sell
2,410,769
-263,068
-10% -$8.48M 3.1% 8
2022
Q4 		$66.7M Sell
2,673,837
-202,800
-7% -$5.41M 2.73% 11
2022
Q3 		$62.6M Buy
2,876,637
+269,507
+10% +$7.1M 2.43% 12
2022
Q2 		$51.3M Sell
2,607,130
-7,900
-0.3% -$185K 1.96% 15
2022
Q1 		$111M Buy
2,615,030
+27,300
+1% +$1.15M 3.45% 6
2021
Q4 		$164M Sell
2,587,730
-205,978
-7% -$12M 3.74% 6
2021
Q3 		$164M Buy
2,793,708
+262,200
+10% +$15.2M 2.86% 11
2021
Q2 		$123M Sell
2,531,508
-71,631
-3% -$3.11M 1.82% 16
2021
Q1 		$101M Sell
2,603,139
-117,350
-4% -$7.06M 1.42% 21
2020
Q4 		$169M Sell
2,720,489
-12,171
-0.4% -$594K 2.04% 13
2020
Q3 		$88.3M Buy
+2,732,660
New +$83.4M 1.62% 17

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Redmile Group's KYMR Position: Q3 2025 in Review

Redmile Group sold out of Kymera Therapeutics (KYMR) in Q3 2025, closing a stake of 803,289 shares — an estimated $35.1M sold.

Redmile Group first reported a position in KYMR in Q3 2020 and held it in 20 quarters. The position peaked at $169M in Q4 2020. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • Redmile Group reported no remaining Kymera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Redmile Group sold 803,289 Kymera Therapeutics shares in Q3 2025, an estimated $35.1M.
  • Redmile Group first reported a position in Kymera Therapeutics in Q3 2020 and held it in 20 quarters.
  • Redmile Group's Kymera Therapeutics position peaked at $169M in Q4 2020.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Redmile Group's 13F filing for Q3 2025, filed 14 Nov 2025.